Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture
Launched by OSLO UNIVERSITY HOSPITAL · Jun 16, 2015
Trial Information
Current as of June 24, 2025
Unknown status
Keywords
ClinConnect Summary
Prospective randomized study between Percutanous Needle Fasciotomy and Xiapex for Dupuytrens contracture.
A total of 50 patiens are to be randomized to eighter percutaneous needle fasciotomy or Xiapex treatment.
The patients randomized to xiapex treatment are treated as described in the product manual. Extentin treatment after one day.
The patients randomized to percutaneous needle fasciotomy are treated with the cutting teqnique: A littel quaddle local anestesia (xylocaine with adrenaline) is to be injected subcutant over the cord. After thet we use a 19G needle to cut the cord sufficie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • symptomatic Dupuytrens contracture with palpable cord, involving MCP, total contracture size over 30 degrees
- Exclusion Criteria:
- • previous treated dupuytrens contracture same hand
- • more than tree fingers involvement
- • we will not include thumbs
- • other things affecting hand function
- • ASA\>3
- • expected to live under five years
- • Tetracycline treatment within two weeks
- • pregnancy
- • nursing
- • allergy to clostridium histolyticum
- • participant in other trial
About Oslo University Hospital
Oslo University Hospital is a leading academic medical center in Norway, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes the development of new therapies and treatment strategies. With a multidisciplinary approach, Oslo University Hospital collaborates with various stakeholders, including researchers, healthcare professionals, and industry partners, to enhance clinical outcomes and contribute to the global medical community. Its dedication to ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and respect for participant welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oslo, , Norway
Patients applied
Trial Officials
hallgeir bratberg, MD
Principal Investigator
Oslo University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials